Notice: This company has been marked as potentially delisted and may not be actively trading. Proteostasis Therapeutics (PTI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends PTI vs. ATOS, DRUG, NLTX, PEPG, SGMT, PBYI, IVA, PYXS, TELO, and MCRBShould you be buying Proteostasis Therapeutics stock or one of its competitors? The main competitors of Proteostasis Therapeutics include Atossa Therapeutics (ATOS), Bright Minds Biosciences (DRUG), Neoleukin Therapeutics (NLTX), PepGen (PEPG), Sagimet Biosciences (SGMT), Puma Biotechnology (PBYI), Inventiva (IVA), Pyxis Oncology (PYXS), Telomir Pharmaceuticals (TELO), and Seres Therapeutics (MCRB). These companies are all part of the "medical" sector. Proteostasis Therapeutics vs. Atossa Therapeutics Bright Minds Biosciences Neoleukin Therapeutics PepGen Sagimet Biosciences Puma Biotechnology Inventiva Pyxis Oncology Telomir Pharmaceuticals Seres Therapeutics Proteostasis Therapeutics (NASDAQ:PTI) and Atossa Therapeutics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations. Is PTI or ATOS more profitable? Atossa Therapeutics' return on equity of -35.74% beat Proteostasis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Proteostasis TherapeuticsN/A -75.39% -55.04% Atossa Therapeutics N/A -35.74%-33.51% Does the MarketBeat Community believe in PTI or ATOS? Proteostasis Therapeutics received 80 more outperform votes than Atossa Therapeutics when rated by MarketBeat users. However, 64.93% of users gave Atossa Therapeutics an outperform vote while only 59.03% of users gave Proteostasis Therapeutics an outperform vote. CompanyUnderperformOutperformProteostasis TherapeuticsOutperform Votes31759.03% Underperform Votes22040.97% Atossa TherapeuticsOutperform Votes23764.93% Underperform Votes12835.07% Do analysts rate PTI or ATOS? Atossa Therapeutics has a consensus target price of $6.75, suggesting a potential upside of 472.03%. Given Atossa Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Atossa Therapeutics is more favorable than Proteostasis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Proteostasis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Atossa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to PTI or ATOS? In the previous week, Atossa Therapeutics had 14 more articles in the media than Proteostasis Therapeutics. MarketBeat recorded 14 mentions for Atossa Therapeutics and 0 mentions for Proteostasis Therapeutics. Atossa Therapeutics' average media sentiment score of 0.51 beat Proteostasis Therapeutics' score of 0.00 indicating that Atossa Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Proteostasis Therapeutics Neutral Atossa Therapeutics Positive Which has higher valuation and earnings, PTI or ATOS? Atossa Therapeutics has lower revenue, but higher earnings than Proteostasis Therapeutics. Atossa Therapeutics is trading at a lower price-to-earnings ratio than Proteostasis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProteostasis Therapeutics$5M0.00-$59.13M-$1.16N/AAtossa TherapeuticsN/AN/A-$30.09M-$0.22-5.36 Do institutionals and insiders believe in PTI or ATOS? 16.6% of Proteostasis Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Atossa Therapeutics shares are held by institutional investors. 4.8% of Proteostasis Therapeutics shares are held by insiders. Comparatively, 7.6% of Atossa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, PTI or ATOS? Proteostasis Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Atossa Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. SummaryAtossa Therapeutics beats Proteostasis Therapeutics on 12 of the 16 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Proteostasis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTI vs. The Competition Export to ExcelMetricProteostasis TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.57M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.624.8587.8613.46Price / SalesN/A374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / BookN/A10.216.946.30Net Income-$59.13M$153.61M$119.12M$225.93M Proteostasis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTIProteostasis TherapeuticsN/AN/AN/AN/A$37.57M$5M-0.6244Gap UpATOSAtossa Therapeutics1.2137 of 5 stars$1.18-1.7%$6.75+472.0%+62.2%$148.44MN/A-5.458Analyst DowngradeAnalyst RevisionDRUGBright Minds Biosciences0.8622 of 5 stars$33.25+1.8%N/A+2,513.4%$147.30MN/A0.00N/ANLTXNeoleukin TherapeuticsN/A$15.33-11.0%N/A+30.5%$144.07MN/A-4.9390High Trading VolumePEPGPepGen2.457 of 5 stars$4.40-1.6%$14.67+233.3%-5.6%$143.44MN/A0.0072Analyst ForecastSGMTSagimet Biosciences2.1861 of 5 stars$4.65+2.9%$21.60+364.5%+50.2%$142.62M$2M0.008PBYIPuma Biotechnology4.4141 of 5 stars$2.89+1.8%$7.00+142.2%-27.0%$141.87M$235.60M5.92185Analyst ForecastPositive NewsIVAInventiva3.0751 of 5 stars$2.61-4.7%$14.00+436.4%-31.9%$136.97M$18.91M0.00100News CoverageGap DownPYXSPyxis Oncology1.0178 of 5 stars$2.25-41.1%$9.57+325.4%+165.3%$133.81MN/A-3.7160News CoverageGap UpHigh Trading VolumeTELOTelomir PharmaceuticalsN/A$4.50+7.1%N/AN/A$133.25MN/A0.001News CoverageMCRBSeres Therapeutics3.8903 of 5 stars$0.78-4.2%$5.08+551.6%-16.1%$133.19M$126.32M0.00233Analyst Upgrade Related Companies and Tools Related Companies ATOS Alternatives DRUG Alternatives NLTX Alternatives PEPG Alternatives SGMT Alternatives PBYI Alternatives IVA Alternatives PYXS Alternatives TELO Alternatives MCRB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteostasis Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteostasis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
